Integral Diagnostics (ASX:IDX) share price slides 14% on FY21 earnings

The market has reacted negatively to Integral Diagnostics' FY21 results.

| More on:
falling healthcare asx share price represented by doctor grimacing at x-ray

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Integral Diagnostics Ltd (ASX: IDX) share price is sliding today after the company released its earnings results for the financial year 2021 (FY21).

Right now, the Integral share price is trading at $4.62, 14.44% lower than its previous close.

Integral Diagnostics share price down despite revenue boost

Here's how the diagnostic imaging provider performed in FY21:

Integral Diagnostics received $6.6 million in JobKeeper payments in FY21. Of that, it chose to voluntarily pay back $2.9 million ($2 million after tax).

The company experienced organic revenue growth of 12.2% in Australia and 12.5% in New Zealand. Its average fee per exam also increased by 3.3%. 

The company ended the period with $62.2 million of cash and $137.4 million of debt.

What happened in FY21 for Integral Diagnostics?

FY21 was a busy period for Integral Diagnostics and its share price. 

The company acquired New Zealand-based Ascot Radiology in September. Integral said Ascot's operating performance in 9 diagnostic imaging clinics was in line with expectations. 

In February, Integral also announced a joint venture with UK-based Medica Group. The companies will provide teleradiology reporting services and additional reporting capacity in Australia, New Zealand, the United Kingdom, and Ireland. 

In addition, the company has added new technology to many of its sites during FY21. It installed a 3T non-rebateable MRI at the Spine Centre on the Gold Coast, a second CT in Toowoomba, and a Cardiac CT in Busselton.

Integral also initiated an MRI service for the Western Australia Health Service and replaced an older MRI with a new 3T MRI at Ascot Radiology.

It also opened several new clinics and solidified plans to develop 4 sites in FY22.

What did management say?

Integral CEO and managing director Dr Ian Kadish commented on the results: 

Our financial performance in FY21 was strong. Our patients and referrers were well taken care of, and our teams across the business delivered all that was asked, and more.

COVID-19 outbreaks and associated government lockdowns and border closures all took a toll, team morale was impacted, but the professionalism, dedication and commitment of our doctors and staff has been inspiring.

What's next for Integral Diagnostics?

Here's what those interested in the Integral share price might want to keep an eye on in FY22:

The company believes COVID-19 will continue to impact its business. It notes that the first half of FY22 has already seen its businesses hit with restrictions and closures. 

In FY22, it will focus on organic growth, accelerating digital and AI technologies, strategic expansion opportunities, and its environmental, social and governance strategy.

Integral also expects its business to grow in the longer term due to the growing elderly population. 

It noted that increasing occurrences of chronic disease and promising new digital, imaging, and AI technologies placed it in a strong position.

Additionally, MRI, CT and PET scans are well-positioned for growth from new diagnostic applications in the fields of oncology, cardiology and neurology.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Integral Diagnostics Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Earnings Results

Westpac shares on watch amid $6.99b profit and new buyback

Has the big four bank delivered the goods for investors this year? Let's find out.

Read more »

Woman inspecting packages.
Earnings Results

This top 50 ASX stock is diving 5% despite a strong outlook

Investors were looking for more.

Read more »

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices
Earnings Results

Macquarie share price sinks despite $1.6b half year profit and new buyback

How did this investment bank perform during the first half? Let's find out.

Read more »

A woman holds her hand out under a graphic hologram image of a human brain with brightly lit segments and section points.
Earnings Results

Why the BrainChip share price is in the spotlight this week

Today's reaction is in stark contrast to the day of the release.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A businesswoman ponders why her boat is sinking in the ocean.
Resources Shares

Lake Resources share price sinks on quarterly cash flow news

Let's take a look at the highlights of the company's Q3 update.

Read more »

Lithium ion batteries
Earnings Results

Needs a recharge: Novonix share price sees red after Q3 earnings

Investors were likely expecting a tad more.

Read more »

chip and tech stocks represented by two computer chips side by side
AI Stocks

Up 237% in 2024, why is the Appen share price racing higher again today?

Investors are bidding up Appen shares again today. But why?

Read more »